Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Regulatory Gemish: COVID-19’s big impacts on the FDA and beyond

Regulatory Gemish: COVID-19’s big impacts on the FDA and beyond

FromThe BioWorld Insider Podcast


Regulatory Gemish: COVID-19’s big impacts on the FDA and beyond

FromThe BioWorld Insider Podcast

ratings:
Length:
29 minutes
Released:
Dec 9, 2021
Format:
Podcast episode

Description

Amid industry’s ongoing drive to speed drug discovery, clinical development and commercial success, government regulation can sometimes seem slow moving. But even a quick look at regulatory highlights from 2021 shows nothing could be further from the truth. From COVID-19 and cancer to Aduhelm and the broader health care ecosystem, so much has changed – and not just in the U.S. Join us for perspective on this fast-changing landscape from Peter Pitts, president of the Center for Medicine in the Public Interest, among other roles. “All of a sudden, everybody is a regulatory expert,” he said. Will free beer get us where we need to go? Listen to find out.  Hosted on Acast. See acast.com/privacy for more information.
Released:
Dec 9, 2021
Format:
Podcast episode

Titles in the series (37)

Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation. Hosted on Acast. See acast.com/privacy for more information.